# Cagrilintide

> Long-acting amylin analog studied alongside semaglutide as CagriSema.

- Class: Metabolic
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/cagrilintide

## Overview

Cagrilintide is a 37-amino-acid acylated amylin analog with affinity at all five amylin receptor subtypes. Investigated by Novo Nordisk both as monotherapy and in combination with semaglutide (CagriSema).

Cagrilintide is a long-acting, acylated analog of amylin — the pancreatic hormone co-secreted with insulin that signals satiety and slows gastric emptying. It binds across the amylin and calcitonin receptor subtypes and carries a fatty-acid chain that supports once-weekly dosing.

Developed by Novo Nordisk, it is investigational and studied both on its own and in a fixed combination with semaglutide known as CagriSema, where the amylin and GLP-1 pathways are paired for additive weight effect.

## Mechanism

Amylin and calcitonin receptor agonism → satiety, slowed gastric emptying.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409.2 Da |
| CAS number | 1415456-99-3 |
| PubChem CID | [171397054](https://pubchem.ncbi.nlm.nih.gov/compound/171397054) |

## Research areas

Studied in: Obesity, Combination metabolic therapy.

Guides on this site:

- [Weight Loss & Metabolic Health](https://www.americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.

## Key research

- Satiety signaling — amylin-receptor agonism studied for appetite suppression and slowed gastric emptying.
- Combination therapy — investigated with semaglutide (CagriSema) for additive weight reduction.
- Obesity endpoints — Phase 2 trials reported meaningful mean weight loss alone and in combination.
- Half-life engineering — acylation supports a once-weekly profile.
- Investigational status — not FDA-approved.

## FAQs

### What is cagrilintide?

Cagrilintide is an investigational long-acting amylin analog studied for weight management, both alone and combined with semaglutide (CagriSema).

### What is CagriSema?

CagriSema is the investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1), pairing two appetite pathways for additive effect.

### How does amylin differ from GLP-1?

Both promote satiety, but amylin acts through amylin and calcitonin receptors while GLP-1 acts through the GLP-1 receptor; combining them is studied for complementary effects.

### Is cagrilintide approved?

No — it is investigational. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Cagrilintide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both](https://clinicaltrials.gov/study/NCT06534411) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT06534411
- [A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight](https://clinicaltrials.gov/study/NCT07564414) — RECRUITING · PHASE3 · NCT07564414
- [A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes](https://clinicaltrials.gov/study/NCT07282613) — NOT_YET_RECRUITING · PHASE3 · NCT07282613
- [Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events](https://clinicaltrials.gov/study/NCT07607587) — NOT_YET_RECRUITING · PHASE1 · NCT07607587
- [A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight](https://clinicaltrials.gov/study/NCT07605052) — NOT_YET_RECRUITING · PHASE1 · NCT07605052
- [A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight](https://clinicaltrials.gov/study/NCT06289504) — COMPLETED · PHASE1 · NCT06289504

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/cagrilintide
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.